Oculis Holding AG (OCS) Other Gross PP&E Adjustments (2022 - 2026)
Oculis Holding AG's (OCS) quarterly Other Gross PP&E Adjustments came in at -$3.0 million in Q1 2026, down 122.93% year-on-year from $13.2 million in Q1 2025, and up 2.0% quarter-over-quarter from -$3.1 million in Q4 2025.
Oculis Holding AG (OCS) Other Gross PP&E Adjustments (2022 - 2026) Analysis & Trends
Oculis Holding AG's Other Gross PP&E Adjustments history runs 5 years deep, the most recent figure standing at -$3.0 million for Q1 2026.
- On a quarterly basis, Other Gross PP&E Adjustments fell 122.93% year-over-year to -$3.0 million in Q1 2026; TTM through Mar 2026 was -$3.0 million, a 122.93% decrease from a year earlier, with the FY2025 full-year figure at -$3.0 million, down 100.57% from the prior year.
- Other Gross PP&E Adjustments climbed to -$3.0 million in Q1 2026 per OCS's latest filing, from -$3.1 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$786820.6 in Q4 2022 and bottomed at -$3.2 million in Q3 2025.
- The 5-year median for Other Gross PP&E Adjustments is -$1.4 million (2025), against an average of -$1.6 million.
- Across the five-year window, Other Gross PP&E Adjustments advanced 13.88% in 2025 and tumbled 122.93% in 2026, its largest moves.
- Year by year, Other Gross PP&E Adjustments stood at -$786820.6 in 2022, then fell by 8.18% to -$851152.6 in 2023, then slumped by 74.75% to -$1.5 million in 2024, then sank by 107.18% to -$3.1 million in 2025, then increased by 2.0% to -$3.0 million in 2026.
- Per Business Quant, the three latest OCS Other Gross PP&E Adjustments figures stand at -$3.0 million (Q1 2026), -$3.1 million (Q4 2025), and -$3.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -3.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 35.73 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -1.69 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -67.74 Mn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | -189.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.02 Mn |
| Mar 31, 2026 | -3.02 Mn |
| Dec 31, 2025 | -3.08 Mn |
| Dec 31, 2025 | -3.08 Mn |
| Sep 30, 2025 | -3.22 Mn |
| Sep 30, 2025 | -3.22 Mn |
| Jun 30, 2025 | -1.40 Mn |
| Jun 30, 2025 | -1.40 Mn |
| Mar 31, 2025 | -1.35 Mn |
| Mar 31, 2025 | -1.35 Mn |
| Dec 31, 2024 | -1.49 Mn |
| Dec 31, 2024 | -1.49 Mn |
| Sep 30, 2024 | -1.60 Mn |
| Sep 30, 2024 | -1.60 Mn |
| Jun 30, 2024 | -1.62 Mn |
| Jun 30, 2024 | -1.62 Mn |
| Mar 31, 2024 | -823,745.58 |
| Mar 31, 2024 | -823,745.58 |
| Dec 31, 2023 | -851,152.63 |
| Dec 31, 2023 | -851,152.63 |